Histone methyltransferase inhibitors prevent lens opacity in diabetic cataract rats.
Histone methyltransferase inhibitors may reduce lens opacity in diabetic cataract models, but human studies are needed to confirm clinical relevance.
Where it sits
this study against the rest of the abaloparatide (tymlos) corpusSummary and findings
The study investigated the effects of histone methyltransferase inhibitors on lens opacity in diabetic cataract rats induced by galactose. Four inhibitors, including BIX-01294, were tested for their ability to reduce lens opacity and structural damage. BIX-01294 showed the most significant effect in reducing lens injury and altering gene expression related to lens opacity.
Abstract
<h4>Objective</h4>To investigate the effect and mechanism of histone methylation on galactose-induced lens opacity.<h4>Methods</h4>Lenses from SD rats were cultured in 30 mM galactose medium to induce opacification, with intervention using four histone methyltransferase inhibitors (GSK126, Pinometostat, GSK3326595, BIX-01294). Lens opacity, structural changes (HE staining/transmission electron microscopy (TEM)), differentially expressed genes (high-throughput sequencing), and validated targets (qPCR) were analyzed. A diabetic cataract (DC) rat model was established via intraperitoneal galactose injection, with BIX-01294 intervention. Ocular lesions (fundus/slit-lamp examination), lens structure (HE staining), AR/TNF-α levels (ELISA), and Pikfyve mRNA expression (qPCR) were assessed. Ex vivo, YM201636 (a Pikfyve inhibitor) was used to intervene in galactose-induced opacity, with opacity observation and structural evaluation (HE staining/TEM).<h4>Results</h4>The four histone methyltransferase inhibitors ameliorated lens opacity to varying degrees. HE staining and TEM results showed that histone methyltransferase inhibitors alleviated lens injury, with BIX-01294 exhibiting the most pronounced effect. High-throughput sequencing of the model group and the BIX-01294 intervention group revealed that after BIX-01294 treatment, 113 genes were upregulated and 60 genes were downregulated. qPCR validation showed that mRNA expression levels of Pth1r, Fam111a, Pikfyve, and H19 were significantly downregulated after BIX-01294 intervention. Furthermore, BIX-01294 intervention reduced lens injury, decreased AR activity and TNF-α content, and lowered Pikfyve mRNA expression in DC rats. Intervention with YM201636 (a Pikfyve inhibitor) alleviated galactose-induced lens opacity and improved lens damage in vitro.<h4>Conclusion</h4>Histone methyltransferases are involved in lens opacity in DC rats by regulating Pikfyve gene expression.
Background
The study addresses the role of histone methylation in the development of lens opacity, particularly in the context of diabetic cataracts. Previous research has suggested that epigenetic modifications can influence the progression of cataracts, but the specific mechanisms and potential interventions remain unclear. This study aims to elucidate the role of histone methyltransferases in lens opacity and explore potential therapeutic interventions.
Methods
The study utilized Sprague-Dawley rats, with lenses cultured in a 30 mM galactose medium to induce opacification. Four histone methyltransferase inhibitors were tested: GSK126, Pinometostat, GSK3326595, and BIX-01294. A diabetic cataract model was created via intraperitoneal galactose injection, with BIX-01294 intervention. Outcomes included lens opacity, structural changes, differentially expressed genes, and specific gene expression levels.
Results
BIX-01294 showed the most pronounced effect in reducing lens opacity and structural damage among the tested inhibitors. High-throughput sequencing revealed significant changes in gene expression, with 113 genes upregulated and 60 downregulated after BIX-01294 treatment. The intervention also reduced AR activity, TNF-α content, and Pikfyve mRNA expression in diabetic cataract rats.
Interpretation
The findings suggest that histone methyltransferase inhibitors, particularly BIX-01294, can modulate gene expression and reduce lens opacity in a rat model of diabetic cataracts. While the results are statistically significant, the clinical relevance remains uncertain due to the study's reliance on animal models and surrogate endpoints. Further research in human subjects is necessary to determine the potential therapeutic value.
Key findings
- 113 genes upregulated and 60 genes downregulated after BIX-01294 treatment.
- BIX-01294 significantly reduced AR activity and TNF-α content in DC rats.
- BIX-01294 intervention decreased Pikfyve mRNA expression.
- YM201636 alleviated galactose-induced lens opacity in vitro.
Limitations
- rat model, not human
- surrogate endpoints used
- short-term intervention
- single-site study